103 results about "Alpha globulin" patented technology

The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF / TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.

The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in deficiency in MHC class I expression and function. Also provided are the method of using the cells for transplantation and treating a disease condition.

The invention discloses a pair of transcription activator-like effector nucleases, and encoding genes and application thereof. The pair of transcription activator-like effector nucleases (TALEN) is obtained by fusing a pair of deoxyribonucleic acid (DNA) recognition proteins and two heterologous subunits of a Flavobacterium okeanokoites 1(Fok 1) DNA incision enzyme and can recognize two adjacent loci on goat or sheep beta lactoglobulin gene (BLG) exon2 specifically. When the transcription activator-like effector nucleases are transferred to a host cell simultaneously, the exon2 loci of the BLG gene of the host cell can be targeted by the transcription activator-like effector nucleases, and the targeted loci are subjected to genetic mutation, so that the targeted modification of the goat or sheet BLG gene is realized, and the transcription activator-like effector nucleases have the advantages of high specificity, high targeting efficiency, high accuracy and the like.

A process for modifying the lactoprotein by enzyme method features that the immobilized composite enzyme, the ionically regulatory protein structure and heat treating technique are used as selectively hydrolyze the alpha S-casein and beta-lactoglobulin in lactoprotein, resulting in easy digestion and low sensitization. It can be used for composite milk for baby, old man and patient.

The invention discloses a method for separating and detecting whey proteins, which comprises the following steps: pretreating the whey protein; and completely separating bovine alpha-lactalbumin, bovine beta a-lactoglobulin, and bovine beta b-lactoglobulin in a sample by an ultra-performance liquid chromatography column taking 1.7 mu m ethylidene bridged hybrid (BEH) particles as a filler, and performing section scan by a mass analyzer to quantitate the unmodified bovine lactalbumin and lactoglobulin. In the method, human alpha-lactalbumin is added as internal standard. The method can accurately measure the contents of the three types of unmodified bovine whey proteins in multiple kinds of food, and has simple pretreatment, high sensitivity, quick detection speed and good selectivity.

The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., over-expression of beta-2 microgobulin (B2M), keratin 17 (KRT17), interleukin 8 (IL8), or annexin A2 (ANXA2), and under-expression of cytochrome p450 1B1 (CYP1B1) or laminin gamma-2 (LAMC2) can be indicative of the likelihood a subject has squamous cell carcinoma or a precancerous squamous cell disorder. The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. The expression levels of B2M, CYP1B1, KRT17, IL8, ANXA2, or LAMC2 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia.

The invention provides a polynucleotide comprising a sequence encoding a polypeptide that is capable of high level presentation of antigenic peptides on antigen-presenting cells, wherein the polypeptide comprises a β2-microglobulin molecule that is linked through its carboxyl terminal to a bridge peptide which spans the whole distance to the cell membrane, said bridge peptide being linked to a polypeptide stretch consisting of the full or partial transmembrane and / or cytoplasmic domains selected from the group consisting of a toll-like receptor (TLR) polypeptide, a CD40 polypeptide, and TLR and CD40 polypeptides fused in tandem, that allows the anchorage of the β2-microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising an MHC class I epitope, wherein said antigenic peptide is preferably derived from a tumor-associated antigen or from a pathogenic antigen. Antigen presenting cells and DNA and cellular vaccines for treatment of cancer and infectious diseases, are also provided.

The present invention is directed to 5′ regulatory regions of a cotton seed-specific gene, α-globulin. The 5′ regulatory region, or parts thereof, when operably linked to either the coding sequence of a native gene, heterologous gene or a sequence complementary to a native plant gene, direct expression of the coding sequence or complementary sequence in a plant seed. The regulatory regions are useful in expression cassettes and expression vectors for the transformation of plants. Also provided are methods of modulating the levels of a native or heterologous gene such as a fatty acid synthesis or lipid metabolism gene by transforming a plant with the subject expression cassettes and expression vectors.

Provided are a B cell-derived iPS cell generated using a convenient technique, a technology for providing a human antibody at low cost using the iPS cell, an immunologically humanized mouse prepared using cells differentiated from the iPS cell, and the like. Also provided are a cloned cell obtained by contacting a B cell with nuclear reprogramming factors excluding C / EBPα and Pax5 expression inhibiting substances, particularly nucleic acids that encode Oct3 / 4, Sox2, Klf4 and c-Myc, wherein the cloned cell has an immunoglobulin gene rearranged therein and possesses pluripotency and replication competence (B-iPS cell). Still also provided are a method of producing a monoclonal antibody against a specified antigen, comprising recovering an antibody from a culture of B cells obtained by differentiating a B-iPS cell derived from a B cell immunized with the specified antigen, and a method of generating an immunologically humanized mouse, comprising transplanting to an immunodeficient mouse a human immunohematological system cell obtained by differentiating a B-iPS cell.

Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. The primary product can also contain cleavage sequences such as other proteolytic cleavage or protease recognition sites, or signal peptides which contain recognition sequences for signal peptidases, separating at least two of the multiple protein subunits. The sequences of the inserted auto-processing polypeptides or cleavage sites can be manipulated to enhance the efficiency of expression of the separate multiple protein subunits. Also disclosed are independent aspects of conducting efficient expression, secretion, and / or multimeric assembly of proteins such as immunoglobulins. Where the polyprotein contains immunoglobulin heavy and light chain segments or fragments capable of antigen recognition, in an embodiment a selectable stoichiometric ratio is at least two copies of a light chain segment per heavy chain segment, with the result that the production of properly folded and assembled functional antibody is made. Modified signal peptides, including such from immunoglobulin light chains, are described.

The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and / or preventing various diseases and disorders by administering the humanized anti-αvβ6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin αvβ6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment / prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin αvβ6.

The invention discloses an aptamer probe for detecting alpha-lactalbumin, beta-lactoglobulin and lactoferrin, and belongs to the technical field of IA (immunoassay) of food analysis. The nucleotide sequence of the aptamer probe for detecting alpha-lactalbumin, beta-lactoglobulin and lactoferrin disclosed by the invention is shown as SEQ ID NO. 1-3. According to a method disclosed by the invention,the contents of the alpha-lactalbumin, the beta-lactoglobulin and the lactoferrin can be simultaneously detected quickly and accurately; the method is high in sensitivity, short in detection time andsimple and easy to operate.

This invention provides an HLA class I-expressing non-human animal that can be prepared efficiently in a simple manner within a short period of time, in which the transgene copy number to be introduced thereinto and the integration site of transgene are regulated, and in which the expression level of the transgene and the site of expression thereof are regulated. The invention also provides a method for preparing such non-human animal. In such HLA class I gene knock-in non-human animal, an artificial chimeric gene encoding an artificial chimeric protein comprising a protein composed of β2 microglobulin, HLA class I α1 and α2 regions, and an MHC class I α3 region of a non-human animal ligated in such order from the N terminus is expressed under the control of a transcription regulatory region of β2 microglobulin gene of the non-human animal.

The invention provides an inactivated or attenuated gene functionally linked to a hotspot for somatic hypermutation. Inventive nucleic acids include inactivated genes operatively linked to immunoglobulin gene control elements. Embodiments of the invention include murine models of plasma cell disease and germinal center cell lymphoma.

The invention relates to diagnosis reagent for fetus alpha globulin and discloses fetus alpha globulin detection particles, and in particular anti-AFP antibody-coated light-emitting particles. The invention also discloses the preparation and application of the fetus alpha globulin detection particles. In addition, the invention further discloses an in vitro detction kit for measuring fetus alpha globulin in a sample and a using method of the kit at the same time. The kit can be used in for the quantitative measurement of fetus alpha globulin in human blood serum samples and can be used in cancer auxiliary diagnosis and treatment effect monitoring of cancer patients in combination with other blood serum and clinic information.

An antibody microarray screen including a substrate, monoclonal and polyclonal antibodies that are purified immunoglobins, wherein the antibodies are spotted on predetermined positions on the substrate, and fluids unprocessed for immunoglobulin isolation (e.g., anti-sera, ascites fluids, or hybridoma culture media), wherein the unprocessed fluids are spotted on the predetermined positions on the substrate. Production of drug-metabolizing enzyme antibody microarrays containing closely related cytochromes P450 is disclosed. Methods of manufacturing an antibody microarray, an internal control molecule for use in an antibody microarray, a method of determining optimal spotting concentrations of IgG and a method to increase a detectable signal with microarray analysis are disclosed.

The invention provides a method for knocking out a cattle beta-lactoglobulin gene by using zinc finger nucleases (ZFNs), comprising the following steps of: according to a cattle beta-lactoglobulin gene sequence, designing ZFNs specific site expression vector and transplanting the ZFNs specific site expression vector into cattle fibroblast; and obtaining cells with the beta-lactoglobulin gene knocked out. By using ZFNs mediated gene knockout, one-time transfection can be realized so as to obtain cell clones with biallelic genes knocked out, which is difficultly achieved in the conventional gene targeting process. The drug screening process is saved. The method disclosed by the invention is advantageous for forming monoclonal cells. The process required by cells for resisting drug toxic process is avoided. The method plays a key role in the improvement of subsequent somatic cell nuclear transplantation efficiency and embryonic development quality. Simultaneously, resistance genes are not contained; and the biological safety evaluation process is greatly simplified.

The present invention relates generally to mutagenesis of target genes that enhances the natural mutagenic capabilities of adaptive immune cells by providing a chimeric construct that exploits the ability of molecules such as AID to stimulate diversification and the ability of a second molecule to restrict nuclear activity of the molecules and / or protect cell viability. The invention provides a method for stimulating diversification in expressed genes, such as antibody genes, using polypeptides whose nuclear activity is restricted to specific phases of the cell cycle. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity, or for developing T cells for immunotherapy. The invention provides an improved means of developing a repertoire of variant immunoglobulins and other polypeptides.

Provided are antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3). The anti-Tim-3 antibodies can be used to treat, prevent or diagnose immune, cancerous, infectious diseases or other pathological disorders that may be modulated by Tim-3-mediated functions.

The invention belongs to the field of bacteria / livestock microorganisms, and particularly relates to a bacillus velezensis strain for soybean meal fermentation. The strain is bacillus velezensis DP-2with a preservation number of CGMCC No.17235. The bacillus velezensis strain DP-2 can efficiently secrete neutral protease and alkaline protease, and has a good degradation effect on anti-nutrient substances such as glycinin and beta-conglycinin in soybean meal; and the degradation rate of the glycinin can reach 81%-96%, the degradation rate of the beta-conglycinin can reach 50%-67%, acid-solubleprotein is increased by 5-6 times, the content of nutrient substances in fermented soybean meal can be remarkably increased, the nutrient utilization rate is remarkably increased, and therefore the nutritional value of the soybean meal is improved.

Variable domain murine T-cell receptor genes have been isolated and used to construct cloning and expression vectors. Valpha, Vbeta, and single chain Valpha-Vbeta fragments have been expressed as secreted domains in Escherichia coli using the vectors. The domains are secreted into the culture supernatant in milligram quantities. The single domains and the single chain T-cell receptors are folded into beta-pleated sheet structures similar to those of immunoglobulin variable domains. The secreted fragments may be useful for immunization to generate anti-clonotypic antibodies, in vaccination or for high resolution structural studies. The genes encoding these domains may also serve as templates for in vitro mutagenesis and improvement of affinities of the TCR fragments for their interaction with cognate peptide-MHC complexes.

This invention provides a method for producing a plant with enhanced or suppressed growth through introduction of a mutated gene and a plant including such a mutated gene. This invention provides a method for producing a plant with enhanced growth or suppressed growth. Such method includes a step of introducing a gene encoding a chimeric myosin protein into a host plant so as to transform the host plant, wherein the chimeric myosin protein comprises: a neck domain, a coiled-coil domain, and a globular tail domain from a myosin protein involved in cytoplasmic streaming of a donor plant; and a motor domain from a myosin protein other than the myosin protein of the host plant, which has sliding velocity that is higher or lower, respectively, than that of the myosin protein involved in cytoplasmic streaming of the donor plant.

The present disclosure provides a method for treating lupus, Sjogren's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor alpha (IL-3R alpha) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.

Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and / or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

Disclosed is a method for generating a mutein of a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hNGAL), rat alpha 2- microglobulin-related protein (A2m) and mouse 24p3 / uterocalin (24p3), said mutein having detectable affinity to a given target. The method comprises the step of subjecting the protein to mutagenesis at one or more of the sequence positions which correspond to the sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, resulting in one or more mutein(s) of the protein. Also disclosed are muteins obtainable by this method.

The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.

The invention discloses ferritin-based monofunctionalized magnetic nanometer particle. The ferritin-based monofunctionalized magnetic nanometer particle comprises a monofunctionalized ferritin shell and a magnetic nanometer particle core. The monofunctionalized ferritin shell is an asymmetric globulin with a tetrahedral structure. The asymmetric globulin mainly comprises one mutant Dps subunit and eleven wild Dps subunits. The Dps is a starvation-induced DNA binding protein. The ferritin-based monofunctionalized magnetic nanometer particle is prepared from biomacromolecule-protein as a template material, can be reconstructed easily, can be operated conveniently, is convenient for large-scale acquisition, has only one functional group and has an important meaning for follow-up controllable assembling.

The present application provides an infant milk protein partially hydrolyzed formula for special medical use comprising hydrolyzed whey protein prepared from alkaline protease or trypsin hydrolyzed whey protein. According to the formula food disclosed by the invention, good flavor is maintained through moderate hydrolysis, and meanwhile, the sensitization of beta-lactoglobulin is effectively reduced.